NEW YORK (GenomeWeb) – Researchers from the Phase III EURTAC study have published a secondary analysis demonstrating high sensitivity and specificity of blood-based EGFR testing compared to the initial tissue testing performed in the trial.
The study also supports growing evidence that the type of EGFR mutation a patient has, either in tumor tissue or in circulating DNA, may be associated with much different responses to the EGFR inhibitors.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
